About Contact Us Careers

HIV Drugs Market Analysis

Request Free Sample Copy

Report ID: 162
Published Date: Sep 05, 2024
Report Format: PDF, PPT

Buy Now

HIV Drugs Market Analysis

The HIV drugs market is segmented by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and others. Out of which, the hospital pharmacies sub-segment is anticipated to hold the largest share in the market during the forecast period on account of the growing number of HIV patients. A large number of HIV patients get admitted to hospitals is estimated to boost the market growth.

Our in-depth analysis of the global market includes the following segments:

Medication Class	Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Multi-Class Combination Drugs Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Protease Inhibitors (PIs) Entry Inhibitors HIV Integrase Strand Transfer Inhibitors
Distribution Channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies Others

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

HIV Drugs Market Size | Growth Forecast Report 2036

Author Credits: Radhika Pawar

Report ID: 162
Published Date: Sep 05, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of HIV drugs is evaluated at USD 36.3 billion.

HIV Drugs Market size was valued at USD 34.61 billion in 2023 and is set to cross USD 74.73 billion by 2036, registering more than 6.1% CAGR during the forecast period i.e., between 2024-2036. The surging AIDS cases worldwide will impel the market growth.

North America is likely to dominate majority revenue share by 2036, on the back of presence of an ultra-modern healthcare system.

The major players in the market are F. Hoffmann-La Roche Ltd, Cipla Inc., Teva Pharmaceuticals Industries Ltd. and Janssen Global Services, LLC.

Inquiry Before Buying Request Free Sample